Responses
Poster Presentation
Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)
Compose a Response to This Article
Other responses
No responses have been published for this article.